PDE-5 inhibitor use shows no effect on BPH therapy outcomes

On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.

Related Videos

Related Content

Advertisement

January 18th 2025

Leveraging the full potential of APPs: Mark Edney, MD, on tips for successful collaboration

Mark T. Edney, MD

"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 17th 2025

Illuccix approved in Europe for detection of PSMA-positive lesions

Hannah Clarke

The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 16th 2025

Addition of PSMA PET led to notable stage migration in mHSPC, study shows

Hannah Clarke

In total, 40.3% of patients experienced a change in staging between initial assessment on conventional imaging and PSMA PET.

January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke

The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.

Related Content

Advertisement

January 18th 2025

Leveraging the full potential of APPs: Mark Edney, MD, on tips for successful collaboration

Mark T. Edney, MD

"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 17th 2025

Illuccix approved in Europe for detection of PSMA-positive lesions

Hannah Clarke

The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 16th 2025

Addition of PSMA PET led to notable stage migration in mHSPC, study shows

Hannah Clarke

In total, 40.3% of patients experienced a change in staging between initial assessment on conventional imaging and PSMA PET.

January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke

The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.